-
PBA-Targeted PAD4 Inhibitors Block Tumor NETs
2026-09-09
This study developed phenylboronic acid-modified PAD4 inhibitors designed to preferentially target tumor-associated biology while suppressing the PAD4–H3cit–NET pathway in neutrophils. The lead compound 5i reduced tumor growth and lung metastasis in mouse models, highlighting a strategy for improving PAD4 inhibitor selectivity without relying solely on direct tumor-cell killing.
-
Neuritin, ER Stress, and Early Brain Injury After SAH
2026-09-09
This study identifies endoplasmic reticulum stress-related inflammatory signaling as a mechanistic link between subarachnoid hemorrhage, neuroinflammation, and neuronal apoptosis. Its central finding is that Neuritin overexpression suppresses three NF-κB-associated ER stress pathways, providing a framework for interpreting neuroprotective interventions in early brain injury.
-
FGF19-ELF4 Signaling Drives Colorectal Cancer Metastasis
2026-09-08
This study identifies an FGF19–ELF4–FGFR4/SRC signaling circuit that links an extracellular growth-factor signal to transcriptional control of colorectal cancer metastasis. Its combination of clinical profiling, functional models, RNA sequencing, promoter assays, and chromatin immunoprecipitation provides a mechanistic basis for testing dual FGFR4 and SRC inhibition.
-
Medroxyprogesterone Acetate: A Mechanistic Assay Guide
2026-09-08
Medroxyprogesterone acetate (MPA) is more than a progestin stimulus: it is a useful mechanistic probe for separating progesterone receptor, glucocorticoid receptor, renal, reproductive, and neural responses. This guide integrates MPA assay design with a recent multi-omics study of endometrial stromal cell senescence to improve causal interpretation.
-
Plant Cell Lysis Buffer for WB and IP Workflow
2026-09-07
Build cleaner Western blotting, immunoprecipitation, co-IP, and ELISA workflows from plant tissues, protoplasts, or compatible non-plant samples. This non-denaturing formulation combines 1% Triton X-100 with protease and phosphatase inhibitors to support both quantitative protein detection and native interaction studies.
-
Pepstatin A: Designing Mechanism-Resolved Assays
2026-09-05
Pepstatin A is an aspartic protease inhibitor used to interrogate pepsin, renin, HIV protease, and cathepsin D activity. This guide connects mechanism-based inhibitor experiments with the assay-quality principles demonstrated by an optimized GRO-seq workflow, helping researchers separate biological effects from measurement artifacts.
-
HyperScribe All in One mRNA Synthesis Kit
2026-09-05
The HyperScribe All in One mRNA Synthesis Kit is an ARCA capped mRNA synthesis kit that combines T7 transcription, co-transcriptional capping, DNase I treatment, and enzymatic polyadenylation. K1063 supports up to 25 reactions at 20 μL each and reports up to 50 μg of RNA per reaction with 1 μg of control template.
-
PreScission Protease (PSP) Workflow Guide
2026-09-04
PreScission Protease (PSP) provides sequence-specific removal of compatible fusion tags from recombinant proteins through HRV 3C protease activity. It is suited to low-temperature protein purification workflows with an engineered recognition site, but it should not be treated as a universal protease or used without construct-specific cleavage and stability checks.
-
High Viscosity, P-gp, and Cancer Chemoresistance
2026-09-04
A 2026 study identifies extracellular fluid viscosity as a mechanical regulator of chemoresistance, linking tumor-like viscosity to membrane tension, TRPV4–Ca2+ signaling, YAP activation, and increased P-glycoprotein expression. The findings provide a mechanistic framework for studying how physical properties of the tumor microenvironment alter doxorubicin response and suggest that P-gp inhibition can be used as a complementary tool in follow-up experiments.
-
Y-27632 for Reliable Cell Assays
2026-09-03
This scenario-based guide explains how Y-27632 supports reproducible viability, proliferation, cytotoxicity, and cytoskeletal studies while clarifying important interpretation limits. It provides practical handling and selection guidance for SKU B1293, including concentration, exposure, controls, and vendor-comparison considerations.
-
Triptolide (PG490) Research Workflow Guide
2026-09-02
Triptolide (PG490) gives researchers a nanomolar perturbation tool for transcription, tumor invasion, immune-cell apoptosis, and inflammatory signaling studies. This guide translates its mechanism into practical workflows while using the acute pancreatitis literature to define pathway controls, assay choices, and important limitations.
-
Praeruptorin A Workflows for Inflammation & Cancer
2026-09-02
Praeruptorin A supports mechanism-led workflows spanning intestinal barrier repair, ferroptosis, cardiomyopathy research, and hepatocellular carcinoma invasion. This guide converts its multi-target profile into practical dosing, assay, validation, and troubleshooting strategies.
-
EPZ5676: Rewiring H3K79 and Immune Biology
2026-09-02
EPZ5676 is a highly selective DOT1L inhibitor that connects H3K79 methylation control with MLL-rearranged leukemia biology and emerging innate immune mechanisms in multiple myeloma. This thought-leadership guide translates its biochemical selectivity into experimental design, biomarker strategy, and cautious opportunities for combination research.
-
Dual Recombinase Tracing Finds No Postnatal Neo-oogenesis
2026-09-01
Xie, Zhou, and Zheng used orthogonal Cre-loxP and Dre-rox lineage-tracing systems to test whether mouse ovaries generate new oocytes after birth. Across physiological aging and busulfan-induced ovarian injury, they detected no labeled growing oocytes or metaphase II eggs, strengthening the evidence against in vivo postnatal neo-oogenesis in mice while clarifying the limits of extrapolation to human reproduction.
-
SB 431542: ALK5 Inhibitor Workflow for LUAD
2026-08-31
Use SB 431542 to connect receptor-level TGF-β blockade with Smad2 readouts, tumor-cell phenotyping, and mechanistic studies of early-stage lung adenocarcinoma. This workflow translates the LINC01977 super-enhancer findings into practical inhibition, dosing, validation, and troubleshooting decisions.